CN112956686A - Bowel relaxing composition and preparation method thereof - Google Patents

Bowel relaxing composition and preparation method thereof Download PDF

Info

Publication number
CN112956686A
CN112956686A CN202110285614.9A CN202110285614A CN112956686A CN 112956686 A CN112956686 A CN 112956686A CN 202110285614 A CN202110285614 A CN 202110285614A CN 112956686 A CN112956686 A CN 112956686A
Authority
CN
China
Prior art keywords
powder
fullerene
bowel
relaxing
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110285614.9A
Other languages
Chinese (zh)
Inventor
黄佳梅
黎小青
朱常锋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiamen Fuci Biotechnology Co ltd
Original Assignee
Xiamen Fuci Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiamen Fuci Biotechnology Co ltd filed Critical Xiamen Fuci Biotechnology Co ltd
Priority to CN202110285614.9A priority Critical patent/CN112956686A/en
Publication of CN112956686A publication Critical patent/CN112956686A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/20—Agglomerating; Granulating; Tabletting
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention belongs to the field of food, and particularly relates to a composition for relaxing bowel and a preparation method thereof. The bowel relaxing composition contains 20-75 wt% of fullerene microcapsule powder, 20-50 wt% of water-soluble dietary fiber, 0.01-1 wt% of L-arabinose, 0.5-15 wt% of stachyose and 2-20 wt% of fruit and vegetable powder based on the total weight of the bowel relaxing composition. The composition for relaxing bowel provided by the invention can regulate intestinal flora, promote intestinal peristalsis, has the effect of relaxing bowel, can improve constipation, and is safe to human bodies without toxic and side effects.

Description

Bowel relaxing composition and preparation method thereof
Technical Field
The invention belongs to the field of food, and particularly relates to a composition for relaxing bowel and a preparation method thereof.
Background
Constipation is a common disease of intestinal dysfunction, and the incidence rate of constipation is on a rising trend year by year along with the influence of factors such as improvement of living standard of people, change of dietary structure, acceleration of living rhythm, social psychology and the like. The incidence rate of constipation of adults in China is 3.2-11.6%, the prevalence rate of old people is 11.5%, and the prevalence rate of people over 70 years old is 11.7-19.5%. Although constipation can not directly cause death and endanger life, the harm to human bodies is not visible, and constipation can bring pain to human bodies and reduce life quality, and becomes an important disease affecting life quality of modern people. At present, products for preventing constipation mainly comprise medicines, Chinese herbal medicines for relaxing bowel, dietary fibers and the like. However, certain side effects of the drugs and some Chinese herbal medicines for relaxing bowel generally exist, for example, the drugs can damage intestinal mucosa, influence the intestinal micro-ecological environment, cause electrolyte flocculation, have drug dependence and the like, and are not suitable for long-term eating. At present, the reasonable adjustment of the dietary structure and the intake of sufficient dietary fiber are one of the important measures for relieving and preventing constipation.
Disclosure of Invention
The invention aims to overcome the defect that the prior art adopts medicines and certain Chinese herbal medicines for relaxing bowel to treat constipation has side effects, and provides a composition for relaxing bowel, which can regulate intestinal flora, promote intestinal peristalsis, has the effect of relaxing bowel, can improve constipation and is safe to human bodies and free of toxic and side effects, and a preparation method thereof.
The bowel relaxing composition contains 20-75 wt% of fullerene microcapsule powder, 20-50 wt% of water-soluble dietary fiber, 0.01-1 wt% of L-arabinose, 0.5-15 wt% of stachyose and 2-20 wt% of fruit and vegetable powder. Specifically, the fullerene microcapsule powder may be 20 to 75 wt%, specifically 20 wt%, 25 wt%, 30 wt%, 35 wt%, 40 wt%, 45 wt%, 50 wt%, 55 wt%, 60 wt%, 65 wt%, 70 wt%, 75 wt%, or the like, preferably 30 to 75 wt%, more preferably 40 to 75 wt%, and most preferably 50 to 75 wt%. The content of the water-soluble dietary fiber is 20-50 wt%, specifically 20 wt%, 25 wt%, 30 wt%, 35 wt%, 40 wt%, 45 wt%, 50 wt%, etc., preferably 25-45 wt%, more preferably 30-45 wt%. The content of the L-arabinose is 0.01 to 1 wt%, specifically 0.01 wt%, 0.05 wt%, 0.1 wt%, 0.2 wt%, 0.3 wt%, 0.4 wt%, 0.5 wt%, 0.6 wt%, 0.7 wt%, 0.8 wt%, 0.9 wt%, 1.0 wt%, etc., preferably 0.05 to 0.8 wt%, more preferably 0.1 to 0.5 wt%, most preferably 0.15 to 0.5 wt%. The content of stachyose is 0.5-15 wt%, specifically 0.5 wt%, 1 wt%, 2 wt%, 3 wt%, 4 wt%, 5 wt%, 6 wt%, 7 wt%, 8 wt%, 9 wt%, 10 wt%, 11 wt%, 12 wt%, 13 wt%, 14 wt%, 15 wt%, etc., preferably 5-12 wt%, more preferably 8-12 wt%. The content of the fruit and vegetable powder is 2 to 20 wt%, specifically 2 wt%, 3 wt%, 4 wt%, 5 wt%, 6 wt%, 7 wt%, 8 wt%, 9 wt%, 10 wt%, 11 wt%, 12 wt%, 13 wt%, 14 wt%, 15 wt%, 16 wt%, 17 wt%, 18 wt%, 19 wt%, 20 wt%, etc., preferably 3 to 15 wt%, more preferably 4 to 10 wt%, most preferably 5 to 10 wt%.
Fullerene microcapsule powder
The fullerene microcapsule powder contains a fullerene compound, edible vegetable oil, an edible emulsifier, wall materials and an optional stabilizer.
In a preferred embodiment, the total content of the fullerene compound and the edible vegetable oil is 10 to 80 wt% and the content of the fullerene compound is 0.1 to 5 wt%, the content of the edible emulsifier is 0.01 to 5 wt%, the content of the wall material is 0.01 to 80 wt%, and the content of the stabilizer is 0.01 to 20 wt%, based on the total weight of the fullerene microcapsule powder.
In a preferred embodiment, the fullerene compound is selected from C60And derivatives thereof, C70And at least one of a derivative thereof, a fullerene metal derivative, a fullerene oxygen-containing derivative, a fullerene modified or included with an organic compound, and a fullerene derivative modified or included with an organic compound. Wherein the oxygen atom in the fullerene oxygen-containing derivative is connected with the carbon atom on the fullerene skeleton or bonded with the alkylene chain. The organic compound in the fullerene and fullerene derivative modified or included by the organic compound is preferably cyclodextrin and/or crown ether.
In a preferred embodiment, the edible vegetable oil is selected from at least one of olive oil, sea buckthorn seed oil and camellia seed oil.
In a preferred embodiment, the edible emulsifier is selected from at least one of sucrose fatty acid ester, polyglycerol fatty acid ester, glycerol fatty acid ester, polyoxyethylene sorbitan fatty acid ester, sodium caseinate, lecithin, sodium stearate, monoglyceride organic acid fatty acid ester, betaine, amino acid salt, succinic acid glycerol fatty acid ester, sodium stearoyl lactylate, tween-80, span-80, polyglycerol ester, propylene glycol fatty acid ester and polysorbate fatty acid ester; or the edible emulsifier is preferably A or a mixture of A and B, wherein A is one or two of fructo-oligosaccharide, resistant dextrin and skimmed milk powder, and B is one of sodium caseinate, mono-diglycerol fatty acid ester, sodium starch octenyl succinate, ascorbic acid, sodium ascorbate, phospholipid, natural vitamin E, sodium tripolyphosphate and ascorbyl palmitate.
In a preferred embodiment, the wall material is selected from at least one of maltodextrin, soy protein isolate, gum arabic, β -cyclodextrin, starch, whey protein concentrate, dextrin, corn syrup, gelatin, sodium carboxymethylcellulose, xanthan gum, agar, carrageenan, chitosan, starch octenylsuccinate, guar gum, seaweed gum, alginate, milk protein, casein, gluten protein, gliadin, cocoa butter, caseinic acid, vegetable protein, lactose, sucrose, maltose, methyl cellulose, ethyl cellulose, methylhydroxypropyl cellulose, carboxymethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, crystalline cellulose, and water-soluble dietary fibers, particularly preferably two or more of soybean protein isolate, xanthan gum, modified starch, gelatin, carboxymethyl cellulose and maltodextrin.
In a preferred embodiment, the stabilizer is selected from at least one of erythorbic acid and salts thereof, gallic acid and derivatives thereof, gluconic acid, sodium tripolyphosphate, complex phosphates, dipotassium hydrogen phosphate, sodium polyphosphate, sodium metaphosphate, sodium carboxymethylcellulose, and agar.
The fullerene microcapsule powder can be obtained commercially, or can be prepared by various methods known in the art, for example, the method disclosed in CN 110301483A.
Based on the total weight of the composition for relaxing bowel, the content of the fullerene microcapsule powder is 20-75 wt%, more preferably 30-75 wt%, further preferably 40-75 wt%, and most preferably 50-75 wt%.
Water-soluble dietary fiber
The water-soluble dietary fiber has many hydrophilic genes in molecules, has water absorption, water-containing property and expansibility, can increase the volume of excrement and the defecation speed, relieve the pressure in the rectum and the urinary system, relieve the urinary system diseases such as cystitis, kidney stone, vesical stone and the like, and simultaneously, quickly discharge toxins out of the body to prevent constipation and rectal cancer.
Specific examples of the water-soluble dietary fiber include, but are not limited to: at least one of acacia gum, pectin, carrageenan, guar gum, flaxseed gum, carrageenan, guava gum, xanthan gum, agar, fructo-oligosaccharide, oat beta-glucan, polydextrose, inulin, resistant dextrin, xylo-oligosaccharide, galacto-oligosaccharide, stevioside, soy oligosaccharide, isomalto-oligosaccharide, resistant starch, fungal polysaccharide, chitosan, konjac powder, sodium alginate and sodium alginate.
The content of the water-soluble dietary fiber is 20-50 wt%, more preferably 25-45 wt%, and most preferably 30-45 wt% based on the total weight of the composition for relaxing bowel.
L-arabinose
The L-arabinose can inhibit the metabolism and absorption of sucrose and control the rise of blood sugar. Naturally occurring arabinose is in the L-form, which is not metabolized in the animal body, and is sweet but non-caloric. In addition, it inhibits sucrase in the intestinal tract in a non-competitive manner, thereby inhibiting the absorption of sucrose in the small intestine. L-arabinose hinders the digestion and absorption of sucrose, and reduces the energy available to the body, thus reducing the possibility of weight gain and facilitating weight control. The L-arabinose can inhibit sucrose metabolism, and sucrose which is not decomposed in small intestine is decomposed by microorganisms in large intestine to produce large amount of organic acid and CO2、H2Isogas, resulting in osmotic pressure in the intestineThe excrement is softened, the excrement discharge is accelerated, and the frequency and the weight of the excrement are increased.
The content of the L-arabinose is 0.01 to 1 wt%, more preferably 0.05 to 0.8 wt%, further preferably 0.1 to 0.5 wt%, and most preferably 0.15 to 0.5 wt% based on the total weight of the composition for relaxing bowel.
Stachyose
The stachyose is not absorbed in intestinal tract, and can be partially or completely fermented by colonic flora to produce a large amount of short chain fatty acid, methane, carbon dioxide and other gases, so as to stimulate intestinal wall, promote intestinal peristalsis, push food residues into excrement, facilitate defecation and improve functional constipation.
The content of stachyose is 0.5-15 wt%, preferably 5-12 wt%, and more preferably 8-12 wt% based on the total weight of the composition for relaxing bowel.
Fruit and vegetable powder
The fruit and vegetable powder is functional nutritional powder with good flavor and rich nutrition, is easy to absorb, and can improve the intestinal environment of a human body and improve constipation. Specific examples of the fruit and vegetable powder include, but are not limited to: at least one of apple powder, kiwi fruit powder, mulberry powder, fig powder, red date powder, medlar powder, lily powder, yam powder, carrot powder, celery powder, citrus reticulata powder, grape powder, cane shoot powder, lemon powder, balsam pear powder, pumpkin powder, tomato powder, strawberry powder, blueberry powder, watermelon powder, cherry powder, cranberry powder, tangerine peel powder, kumquat powder, passion fruit powder, mango powder, papaya powder, cantaloupe powder, banana powder, pineapple powder, turmeric powder, carambola powder, cucumber powder, guava powder, cabbage cooked powder, crowndaisy chrysanthemum powder, Chinese cabbage powder, lettuce cooked powder, black sesame cooked powder, blackberry powder, lotus root powder, cinnamon powder, white radish cooked powder, mangosteen powder and litchi powder.
Based on the total weight of the composition for relaxing bowel, the content of the fruit and vegetable powder is 2-20 wt%, preferably 3-15 wt%, more preferably 4-10 wt%, and most preferably 5-10 wt%.
In a preferred embodiment, the composition for relaxing bowel further comprises silicon dioxide, and the silicon dioxide is added to improve the fluidity of each component, so that each component is dispersed more uniformly, the activity of each component is exerted more effectively, and the constipation condition is improved more effectively. The preferable mass ratio of the fullerene microcapsule powder to the silicon dioxide is (98-99.5 wt%) (0.5-2 wt%).
The invention also provides a preparation method of the composition for relaxing bowel, which comprises the step of uniformly mixing all the components in the composition for relaxing bowel.
In a preferred embodiment, the components of the bowel relaxing composition are mixed uniformly as follows:
s1, uniformly mixing the fullerene microcapsule powder with silicon dioxide, and granulating by a boiling granulator to obtain fullerene microcapsule powder particles;
s2, mixing the fullerene microcapsule powder, water-soluble dietary fiber, L-arabinose, stachyose and fruit and vegetable powder uniformly to obtain the composition for relaxing bowel.
In a preferred embodiment, in step S1, the mass ratio of the fullerene microcapsule powder to the silicon dioxide is (98-99.5 wt%): 0.5-2 wt%.
In a preferred embodiment, the mixing in step S1 and step S2 is performed in a three-dimensional motion mixer, and the mixing conditions include a rotation speed of 30 to 50Hz and a time of 10 to 60 min.
The composition for relaxing bowel provided by the invention can regulate intestinal flora, promote intestinal peristalsis, has the effect of relaxing bowel, can improve constipation and is safe to human bodies without toxic and side effects.
Detailed Description
The present invention will be described in detail below by way of examples. The examples of embodiments are intended to be illustrative of the invention and are not to be construed as limiting the invention. The examples do not specify particular techniques or conditions, and are performed according to the techniques or conditions described in the literature in the art or according to the product specifications. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products commercially available.
Preparation example 1: this preparation example is used to illustrate the preparation process of fullerene microcapsule powder.
Accurately weighing 1.8kg of sea buckthorn seed oil and 2.34g of fullerene, pouring the weighed sea buckthorn seed oil and fullerene into a mixing tank, starting a stirring switch of the mixing tank, and mixing and stirring for 1 hour to fully and uniformly mix materials in the tank. And after the mixing is finished, putting the obtained fullerene sea-buckthorn seed oil into another mixing tank, accurately weighing 41 wt% of maltodextrin, 15 wt% of casein acid, 1 wt% of dipotassium hydrogen phosphate and 2 wt% of mono-diglycerol fatty acid ester, and adding 48L of water to mix and stir the solution to prepare emulsion. And (3) putting the emulsion in the mixing tank into a colloid mill for emulsification, and passing through the colloid mill for 3 times to fully dissolve the water phase and the oil phase. Immediately carrying out high-pressure homogenization on the emulsion subjected to the colloid mill for 3 times by using a high-pressure homogenizer, wherein the homogenization pressure is controlled to be 30-35 MPa. And (3) carrying out spray drying on the homogenized emulsion, setting the air inlet temperature of a spray dryer to be 150 ℃, setting the air outlet temperature to be 90 ℃, and obtaining the fullerene microcapsule powder after spray drying.
Preparation example 2: this preparation example is used to illustrate the preparation process of fullerene microcapsule powder.
Accurately weighing 1.8kg of camellia seed oil and 2.7g of fullerene, pouring the weighed camellia seed oil and fullerene into a mixing tank, starting a stirring switch of the mixing tank, and mixing and stirring for 1 hour to fully and uniformly mix materials in the tank. And after mixing, putting the obtained fullerene camellia seed oil into another mixing tank, accurately weighing 48.7 wt% of maltodextrin, 10 wt% of casein acid, 1 wt% of dipotassium hydrogen phosphate and 2 wt% of mono-diglycerol fatty acid ester, and adding 48L of water to mix and stir the solution to prepare emulsion. And (3) putting the emulsion in the mixing tank into a colloid mill for emulsification, and passing through the colloid mill for 3 times to fully dissolve the water phase and the oil phase. Immediately carrying out high-pressure homogenization on the emulsion subjected to the colloid mill for 2-3 times by using a high-pressure homogenizer, wherein the homogenization pressure is controlled at 30-35 MPa. And (3) carrying out spray drying on the homogenized emulsion, wherein the air inlet temperature of a spray dryer is set to be 130-150 ℃, and the air outlet temperature is set to be 90-100 ℃. The powder after spray drying is the fullerene micro-capsule powder.
Preparation example 3: this preparation example is used to illustrate the preparation process of fullerene microcapsule powder.
Accurately weighing 1.8kg of olive oil and 3.6g of fullerene, pouring the weighed olive oil and fullerene into a mixing tank, starting a stirring switch of the mixing tank, and mixing and stirring for 1 hour to fully and uniformly mix the materials in the tank. After mixing, putting the obtained fullerene olive oil into another mixing tank, accurately weighing 62.7 wt% of maltodextrin, 5 wt% of casein acid, 1 wt% of dipotassium hydrogen phosphate and 2 wt% of mono-diglycerol fatty acid ester, and adding 48L of water to mix and stir the solution to prepare emulsion. And (3) putting the emulsion in the mixing tank into a colloid mill for emulsification, and passing through the colloid mill for 3 times to fully dissolve the water phase and the oil phase. Immediately carrying out high-pressure homogenization on the emulsion subjected to the colloid mill for 2-3 times by using a high-pressure homogenizer, wherein the homogenization pressure is controlled at 30-35 MPa. And (3) carrying out spray drying on the homogenized emulsion, wherein the air inlet temperature of a spray dryer is set to be 130-150 ℃, and the air outlet temperature is set to be 90-100 ℃. The powder after spray drying is the fullerene micro-capsule powder.
Preparation example 4: this preparation example is used to illustrate the preparation process of fullerene microcapsule powder.
Accurately weighing 1.8kg of nutritional compound oil (olive oil: linseed oil: xanthoceras sorbifolia bunge oil in a volume ratio of 5:3: 2)) and 3.6g of fullerene, pouring the weighed product into a mixing tank, starting a stirring switch of the mixing tank, and mixing and stirring for 1 hour to fully and uniformly mix the materials in the tank. After mixing, the obtained fullerene compound oil is put into another mixing tank, 42 wt% of maltodextrin, 15 wt% of casein acid, 1 wt% of dipotassium hydrogen phosphate and 2 wt% of mono-diglycerol fatty acid ester are accurately weighed, and 48L of water is added to mix and stir the solution to prepare emulsion. And (3) putting the emulsion in the mixing tank into a colloid mill for emulsification, and passing through the colloid mill for 3 times to fully dissolve the water phase and the oil phase. Immediately carrying out high-pressure homogenization on the emulsion subjected to the colloid mill for 2-3 times by using a high-pressure homogenizer, wherein the homogenization pressure is controlled at 30-35 MPa. And (3) carrying out spray drying on the homogenized emulsion, wherein the air inlet temperature of a spray dryer is set to be 130-150 ℃, and the air outlet temperature is set to be 90-100 ℃. The powder after spray drying is the fullerene micro-capsule powder.
Example 1: this example is provided to illustrate the bowel relaxing composition and method of preparation provided by the present invention.
The dosage of the formula is as follows: see table 1.
The preparation method comprises the following steps: uniformly mixing the fullerene microcapsule powder after spray drying with silicon dioxide according to a mass ratio of 99:1, adjusting the rotating speed of a three-dimensional motion mixer to 35Hz, mixing for 20min, and granulating by a boiling granulator after uniform mixing to prepare fullerene microcapsule powder with the average particle size of 0.6 mm. Weighing 50 wt% of fullerene microcapsule powder particles, 35 wt% of water-soluble dietary fiber, 0.3 wt% of L-arabinose, 9.7 wt% of stachyose and 5 wt% of fruit and vegetable powder, putting into a three-dimensional motion mixer, mixing, and adjusting the rotating speed of the three-dimensional motion mixer to 40Hz for 30 min. And (3) sieving the uniformly mixed product by using a circular oscillating screen, and filling the product by using an automatic packaging machine to obtain the bowel relaxing composition.
Example 2: this example is provided to illustrate the bowel relaxing composition and method of preparation provided by the present invention.
The dosage of the formula is as follows: see table 1.
The preparation method comprises the following steps: uniformly mixing the fullerene microcapsule powder after spray drying with silicon dioxide according to a mass ratio of 99:1, adjusting the rotating speed of a three-dimensional motion mixer to 35Hz, mixing for 20min, and granulating by a boiling granulator after uniform mixing to prepare fullerene microcapsule powder with the average particle size of 0.6 mm. Weighing 55 wt% of fullerene microcapsule powder particles, 30 wt% of water-soluble dietary fiber, 0.15 wt% of L-arabinose, 8.85 wt% of stachyose and 6 wt% of fruit and vegetable powder, putting into a three-dimensional motion mixer, mixing, and adjusting the rotating speed of the three-dimensional motion mixer to 40Hz for 30 min. And (3) sieving the uniformly mixed product by using a circular oscillating screen, and filling the product by using an automatic packaging machine to obtain the bowel relaxing composition.
Example 3: this example is provided to illustrate the bowel relaxing composition and method of preparation provided by the present invention.
The dosage of the formula is as follows: see table 1.
The preparation method comprises the following steps: uniformly mixing the fullerene microcapsule powder after spray drying with silicon dioxide according to a mass ratio of 99:1, adjusting the rotating speed of a three-dimensional motion mixer to 35Hz, mixing for 20min, and granulating by a boiling granulator after uniform mixing to prepare fullerene microcapsule powder with the average particle size of 0.6 mm. Weighing 56 wt% of fullerene microcapsule powder particles, 30 wt% of water-soluble dietary fiber, 0.45 wt% of L-arabinose, 8.55 wt% of stachyose and 5 wt% of fruit and vegetable powder, putting into a three-dimensional motion mixer, mixing, and adjusting the rotating speed of the three-dimensional motion mixer to 40Hz for 30 min. And (3) sieving the uniformly mixed product by using a circular oscillating screen, and filling the product by using an automatic packaging machine to obtain the bowel relaxing composition.
Example 4: this example is provided to illustrate the bowel relaxing composition and method of preparation provided by the present invention.
The dosage of the formula is as follows: see table 1.
The preparation method comprises the following steps: uniformly mixing the fullerene microcapsule powder after spray drying with silicon dioxide according to a mass ratio of 99:1, adjusting the rotating speed of a three-dimensional motion mixer to 35Hz, mixing for 20min, and granulating by a boiling granulator after uniform mixing to prepare fullerene microcapsule powder with the average particle size of 0.6 mm. Weighing 50 wt% of fullerene microcapsule powder particles, 34 wt% of water-soluble dietary fiber, 0.3 wt% of L-arabinose, 9.7 wt% of stachyose and 6 wt% of fruit and vegetable powder, putting into a three-dimensional motion mixer, mixing, and adjusting the rotating speed of the three-dimensional motion mixer to 40Hz for 30 min. And (3) sieving the uniformly mixed product by using a circular oscillating screen, and filling the product by using an automatic packaging machine to obtain the bowel relaxing composition.
TABLE 1 amount (wt%) of composition for loosening bowel to relieve constipation added in each example
Item Fullerene microcapsule powder Silicon dioxide Water-soluble dietary fiber L-arabinose Stachyose Fruit and vegetable powder
Example 1 49.5 0.5 35 0.3 9.7 5
Example 2 54.45 0.55 30 0.15 8.85 6
Example 3 55.44 0.56 30 0.45 8.55 5
Example 4 49.5 0.5 34 0.3 9.7 6
Test example
(1) Experimental materials:
1.1.1 Experimental animals
C57BL/6 mouse, clean grade, 60 mice, male, weight range 18-22 g, provided by Shanghai Jihui animal feeding Limited, with license number SCXK (Shanghai) 2017-0012.
1.1.2 animal husbandry management
The experimental animals were housed in animal incubators, 2 animals/cage, and the cages were changed once a week. Environmental conditions: the temperature is 20-21 ℃, the relative humidity is 50-55%, and the fluorescent lamp simulates natural illumination and is replaced within 12 hours. Ingestion and drinking: the animal feed is provided by Wushi laboratory animal trade company, Inc. in Minhou county, and the animal drinking water meets the requirements of national GB5749 biological Drinking Water sanitary Standard, and the animals can freely take the drinking water during the whole period of the test.
1.1.3 instruments and materials
Electronic scale, electronic balance, animal incubator, surgical scissors, ophthalmological forceps, ruler, syringe, activated carbon powder, gum arabic, loperamide (because compound diphenoxylate cannot be purchased, refer to the experimental research of selection of model-making drugs in bowel relaxing function test published by Shanghai disease control center and the public health institute of the university of Compound Dan, the pharmaceutical name is easy Mongolian, the manufacturer: Xian Yang Seng pharmaceutical Co., Ltd., specification: 2 mg/granule)
1.1.4 reagent preparation
Preparing ink: accurately weighing 100g of Arabic gum, adding 800mL of water, boiling until the solution is transparent, weighing 50g of active carbon (powder) and adding the active carbon (powder) into the solution, boiling for three times, adding water to a constant volume of 1000mL after the solution is cooled, storing in a refrigerator at 4 ℃, and shaking uniformly before use.
Preparation of loperamide suspension: dosing was performed as 6mg/kg BW. The loperamide butyric acid capsule contains 2mg of loperamide butyric acid per capsule, 8mg (4 capsules) of loperamide butyric acid is taken, the capsule is unscrewed, the capsule shell is removed, 26.5mL of water is added into the powder to prepare suspension, and the suspension is prepared before use and is fully shaken up when in use.
1.1.5 dose grouping and test sample administration time
Three dose groups (low, medium and high dose groups), one solvent group, one blank control group and one model control group were set for the experiment. One of the dose groups is 10 times of the recommended dose of a human body, and the dose of each group is as follows: the blank control group is irrigated with 0.4mL of sterile water every day, the model control group is irrigated with 0.4mL of sterile water every day, the solvent group is irrigated with 0.4mL of fullerene microcapsule powder solution (750g/L) every day, the low-dose group is irrigated with 0.4mL of bowel relaxing composition solution (250g/L) every day, the medium-dose group is irrigated with 0.4mL of bowel relaxing composition solution (375g/L) every day, and the high-dose group is irrigated with 0.4mL of bowel relaxing composition solution (750g/L) every day. All groups were gavaged continuously for 14 days.
1.1.6 statistical methods
Statistical analysis was performed using SPSS 22.0, data to
Figure BDA0002980329860000081
Is represented by P<A difference of 0.05 is statistically significant. On the premise that a mouse constipation model is established, any one of the results of 5h defecation grain number and defecation weight is positive, and any one of the results of small intestine movement test and defecation time is positive, so that the test object can be judged to have the function of relaxing bowel. Specifically, on the premise that the model is established, when the ink propulsion rate of the mouse in the test sample group is obviously higher than that of the model control group, the positive result of the experiment can be judged; secondly, on the premise that a small intestine constipation model is established, the first grain defecation time of the mouse of the test sample group is obviously shorter than that of a model control group, and the positive result of the index can be judged; the number of the black excrement discharging particles in 5 hours is obviously higher than that of the model control group, and the positive result of the index can be judged; fourthly, the weight of the defecation is obviously higher than that of the model control group within 5 hours, and the positive result of the index can be judged.
(2) Experimental methods
1.2.1 model building
After the test samples were given for 14 days, the mice in each group were fasted for 16 hours. The solvent group, model control group and three dose groups were gavaged with loperamide (6mg/kg BW) and the blank control group was given distilled water.
1.2.2 Small intestine Propulsion experiment
Fasting is carried out for 16 hours before the experiment is finished, a test sample or distilled water is given to each experimental group, the blank control group and the model control group again on the test day, lopiperic acid is given to each experimental group and each model control group after 30 minutes, and distilled water is given to the blank control group; after 0.5 hour, the dosage groups are respectively given with ink containing corresponding tested samples, and the blank control group and the model control group are respectively given with ink for intragastric administration; after 25 minutes, the cervical vertebrae are taken off immediately to kill the animal, the abdominal cavity is opened to separate mesentery, the intestinal canal with the upper end from the pylorus, the lower end to the ileocecal part is cut and placed on a tray, the small intestine is slightly pulled into a straight line, the length of the intestinal canal is measured as the total length of the small intestine, and the length from the pylorus to the front edge of ink is measured as the ink propelling length. The ink propulsion rate was calculated as follows:
Figure BDA0002980329860000091
1.2.3 mouse defecation test
Animals in each group were fasted for 24 hours before the experiment (free drinking water during the period), and after administration of loperamide for 0.5 hour, the ink containing the corresponding test sample was administered to each dose group, and the ink was administered to each of the blank control group and the model control group for gastric lavage. Animals were all housed in a single cage and were fed with normal drinking water. Starting from the ink filling, the time of discharging black feces of the first grain of each animal, the number of discharged black feces in 5 hours and the weight are recorded.
(3) Results
2.1 Small intestine Propulsion test
2.1.1 changes in body weight and mortality of each group during the test period are shown in Table 1. As can be seen from Table 1, all animals in each group grew normally during the administration period, and no weight loss or death occurred in any of the animals.
TABLE 1 animal body weight and mortality
Figure BDA0002980329860000101
2.1.2 the effect of the bowel relaxing composition on the bowel movements of the constipated mice is shown in Table 2. As can be seen from Table 2, the ink propulsion rate of the low, medium and high dose groups is remarkably improved compared with that of the model control group, and the blank control group and the model group have extremely remarkable difference, which indicates that the constipation mice molded by loperamide are successfully molded, and the bowel relaxing composition has the effect of improving the intestinal movement of the constipation mice.
TABLE 2 Effect of bowel relaxing composition on Constipation mouse intestinal motility
Figure BDA0002980329860000102
Grouping Animal number (only) Propelling rate of ink%
Blank control group 10 78.51±1.14**
Model control group 10 53.33±1.48
Solvent set 10 56.25±3.29
Low dose group 10 68.78±4.56*
Middle dose group 10 69.89±2.04*
High dose group 10 69.04±2.58*
2.2 the first black stool time, number of black stools and weight within 5 hours after gastric lavage of mice are shown in Table 3. As can be seen from the results in Table 3, the defecation time of the mice is significantly prolonged after the loperamide is molded, and is relatively accelerated after the composition for relaxing bowel is administered by gastric lavage.
TABLE 3 first-particle black stool time, number of black stools and weight of mice
Figure BDA0002980329860000103
Figure BDA0002980329860000104
Figure BDA0002980329860000111
Note: A. a represents significant difference from the model control group, and B represents significant difference from the solvent group.
The experimental results show that the bowel relaxing composition provided by the invention has the effects of promoting small intestine propulsion and defecation, shortening the first defecation time, increasing the defecation amount and defecation frequency, can effectively improve constipation and is safe to a human body without toxic or side effect.
Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and that variations, modifications, substitutions and alterations can be made in the above embodiments by those of ordinary skill in the art without departing from the principle and spirit of the present invention.

Claims (10)

1. The bowel relaxing composition is characterized by comprising 20-75 wt% of fullerene microcapsule powder, 20-50 wt% of water-soluble dietary fiber, 0.01-1 wt% of L-arabinose, 0.5-15 wt% of stachyose and 2-20 wt% of fruit and vegetable powder, based on the total weight of the bowel relaxing composition.
2. The bowel relaxing composition according to claim 1, wherein the fullerene microcapsule powder contains a fullerene compound, edible vegetable oil, an edible emulsifier, a wall material and an optional stabilizer; preferably, the total content of the fullerene compound and the edible vegetable oil is 10-80 wt% and 0.1-5 wt% of the fullerene compound, the content of the edible emulsifier is 0.01-5 wt%, the content of the wall material is 0.01-80 wt%, and the content of the stabilizer is 0.01-20 wt% based on the total weight of the fullerene microcapsule powder.
3. The bowel relaxing composition according to claim 2,
the fullerene compound is selected from C60And derivatives thereof, C70And at least one of a derivative thereof, a fullerene metal derivative, a fullerene oxygen-containing derivative, a fullerene modified or included by an organic compound, and a fullerene derivative modified or included by an organic compound; the oxygen atom in the fullerene oxygen-containing derivative is connected with the carbon atom on the fullerene skeleton or bonded with an alkylene chain, and the organic compound in the fullerene and the fullerene derivative modified or included by the organic compound is cyclodextrin and/or crown ether;
the edible vegetable oil is at least one selected from olive oil, sea buckthorn seed oil and camellia seed oil;
the edible emulsifier is at least one selected from sucrose fatty acid ester, polyglycerol fatty acid ester, glycerol fatty acid ester, polyoxyethylene sorbitan fatty acid ester, sodium caseinate, lecithin, sodium stearate, monoglyceride organic acid fatty acid ester, betaine, amino acid salt, succinic acid glycerol fatty acid ester, sodium stearoyl lactylate, tween-80, span-80, polyglycerol ester, propylene glycol fatty acid ester and polysorbate fatty acid ester; or the edible emulsifier is A or a mixture of A and B, the A is one or two of fructo-oligosaccharide, resistant dextrin and skimmed milk powder, and the B is one of sodium caseinate, mono-diglycerol fatty acid ester, sodium starch octenyl succinate, ascorbic acid, sodium ascorbate, phospholipid, natural vitamin E, sodium tripolyphosphate and ascorbyl palmitate;
the wall material is selected from at least one of maltodextrin, soybean protein isolate, Arabic gum, beta-cyclodextrin, starch, whey protein concentrate, dextrin, corn syrup, gelatin, sodium carboxymethyl cellulose, xanthan gum, agar, carrageenan, chitosan, starch octenyl succinate, guar gum, alginate, milk protein, casein, mucedin, gliadin, cocoa butter substitute, caseinic acid, vegetable protein, lactose, sucrose, maltose, methyl cellulose, ethyl cellulose, methyl hydroxypropyl cellulose, carboxymethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, crystalline cellulose and water-soluble dietary fiber;
the stabilizer is at least one selected from isoascorbic acid and salts thereof, gallic acid and derivatives thereof, gluconic acid, sodium tripolyphosphate, composite phosphate, dipotassium hydrogen phosphate, sodium polyphosphate, sodium metaphosphate, sodium carboxymethylcellulose and agar.
4. The bowel relaxing composition of claim 1, wherein the water soluble dietary fiber is selected from at least one of acacia gum, pectin, carrageenan, guar gum, flaxseed gum, carrageenan, guaiac gum, xanthan gum, agar, fructo-oligosaccharide, oat beta-glucan, polydextrose, inulin, resistant dextrin, xylo-oligosaccharide, galacto-oligosaccharide, stevioside, soy oligosaccharide, isomalto-oligosaccharide, resistant starch, fungal polysaccharide, chitosan, konjac flour, sodium alginate, and sodium alginate.
5. The bowel relaxing composition according to claim 1, wherein the fruit and vegetable powder is selected from at least one of apple powder, kiwi powder, mulberry powder, fig powder, red date powder, wolfberry powder, lily powder, yam powder, carrot powder, celery powder, citrus reticulata powder, grape powder, zizania latifolia powder, lemon powder, bitter gourd powder, pumpkin powder, tomato powder, strawberry powder, blueberry powder, watermelon powder, cherry powder, cranberry powder, tangerine peel powder, kumquat powder, passion fruit powder, mango powder, papaya powder, cantaloupe powder, banana powder, pineapple powder, turmeric powder, carambola powder, cucumber powder, guava powder, cabbage cooked powder, chrysanthemum powder, water spinach powder, lettuce cooked powder, black sesame cooked powder, blackberry powder, lotus root powder, cinnamon powder, radish cooked powder, mangosteen powder and litchi powder.
6. The bowel relaxing composition according to claim 1, further comprising silicon dioxide; the mass ratio of the fullerene microcapsule powder to the silicon dioxide is (98-99.5 wt%) (0.5-2 wt%).
7. A method for preparing a composition for relaxing bowel according to any one of claims 1 to 6, wherein the method comprises mixing the components of the composition for relaxing bowel uniformly.
8. The method for preparing the composition for relaxing bowel according to claim 7, wherein the components of the composition for relaxing bowel are uniformly mixed in the following way:
s1, uniformly mixing the fullerene microcapsule powder with silicon dioxide, and granulating by a boiling granulator to obtain fullerene microcapsule powder particles;
s2, mixing the fullerene microcapsule powder, water-soluble dietary fiber, L-arabinose, stachyose and fruit and vegetable powder uniformly to obtain the composition for relaxing bowel.
9. The method for preparing a composition for relaxing bowels according to claim 8, wherein in step S1, the mass ratio of the fullerene microcapsule powder to the silicon dioxide is (98-99.5 wt%): (0.5-2 wt%).
10. The method for preparing a composition for relaxing bowels according to claim 8, wherein the mixing of step S1 and step S2 is performed in a three-dimensional motion mixer, and the mixing conditions include a rotation speed of 30 to 50Hz and a time of 10 to 60 min.
CN202110285614.9A 2021-03-17 2021-03-17 Bowel relaxing composition and preparation method thereof Pending CN112956686A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110285614.9A CN112956686A (en) 2021-03-17 2021-03-17 Bowel relaxing composition and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110285614.9A CN112956686A (en) 2021-03-17 2021-03-17 Bowel relaxing composition and preparation method thereof

Publications (1)

Publication Number Publication Date
CN112956686A true CN112956686A (en) 2021-06-15

Family

ID=76278958

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110285614.9A Pending CN112956686A (en) 2021-03-17 2021-03-17 Bowel relaxing composition and preparation method thereof

Country Status (1)

Country Link
CN (1) CN112956686A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114403361A (en) * 2022-02-17 2022-04-29 佳木斯冬梅大豆食品有限公司 Eurotium cristatum fermented soybean meal with constipation relieving effect and preparation process thereof
CN115226899A (en) * 2022-07-25 2022-10-25 鲁东大学 Functional food for people suffering from hypertension and constipation and preparation method thereof

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1327433A (en) * 1999-10-22 2001-12-19 法伊鲁特股份有限公司 Method and apparatus for producing fullerene water
JP2003026411A (en) * 2002-05-13 2003-01-29 Fuairudo Kk Method and device for preparing fullerene water
CN102648748A (en) * 2012-03-08 2012-08-29 中德瑞生物炼制实验室(厦门)有限公司 Food for relaxing bowel
CN103053904A (en) * 2012-12-29 2013-04-24 北京中科邦尼国际科技有限责任公司 Compound functional sugar with function of adjusting intestinal flora
CN103705388A (en) * 2013-12-19 2014-04-09 深圳市通产丽星股份有限公司 Fullerene capsule and application thereof
CN106605909A (en) * 2016-08-01 2017-05-03 西安源森生物科技有限公司 Composition capable of relaxing the bowels, expelling toxin and preventing constipation, as well as preparation method thereof
CN106962935A (en) * 2017-05-15 2017-07-21 华子昂 A kind of health food with function of relaxing bowel
CN108497099A (en) * 2018-03-27 2018-09-07 厦门福慈生物科技有限公司 Fullerene be used to be prepared into the purposes of fullerene microcapsule powder
CN108771247A (en) * 2018-06-29 2018-11-09 山东探克生物科技股份有限公司 A kind of edible fiber products and preparation method thereof with function of relaxing bowel
CN109198356A (en) * 2018-11-23 2019-01-15 温友来 A kind of solid beverage and preparation method thereof with adjusting function of intestinal canal
CN110810855A (en) * 2018-08-14 2020-02-21 烟台药物研究所 Dietary fiber composition with bowel relaxing function

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1327433A (en) * 1999-10-22 2001-12-19 法伊鲁特股份有限公司 Method and apparatus for producing fullerene water
JP2003026411A (en) * 2002-05-13 2003-01-29 Fuairudo Kk Method and device for preparing fullerene water
CN102648748A (en) * 2012-03-08 2012-08-29 中德瑞生物炼制实验室(厦门)有限公司 Food for relaxing bowel
CN103053904A (en) * 2012-12-29 2013-04-24 北京中科邦尼国际科技有限责任公司 Compound functional sugar with function of adjusting intestinal flora
CN103705388A (en) * 2013-12-19 2014-04-09 深圳市通产丽星股份有限公司 Fullerene capsule and application thereof
CN106605909A (en) * 2016-08-01 2017-05-03 西安源森生物科技有限公司 Composition capable of relaxing the bowels, expelling toxin and preventing constipation, as well as preparation method thereof
CN106962935A (en) * 2017-05-15 2017-07-21 华子昂 A kind of health food with function of relaxing bowel
CN108497099A (en) * 2018-03-27 2018-09-07 厦门福慈生物科技有限公司 Fullerene be used to be prepared into the purposes of fullerene microcapsule powder
CN110301483A (en) * 2018-03-27 2019-10-08 厦门福慈生物科技有限公司 The purposes of fullerene compound and fullerene microcapsule powder and its preparation method and application
CN108771247A (en) * 2018-06-29 2018-11-09 山东探克生物科技股份有限公司 A kind of edible fiber products and preparation method thereof with function of relaxing bowel
CN110810855A (en) * 2018-08-14 2020-02-21 烟台药物研究所 Dietary fiber composition with bowel relaxing function
CN109198356A (en) * 2018-11-23 2019-01-15 温友来 A kind of solid beverage and preparation method thereof with adjusting function of intestinal canal

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
鞠美庭等: "《生物质固废资源化技术手册》", 31 March 2014, 天津大学出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114403361A (en) * 2022-02-17 2022-04-29 佳木斯冬梅大豆食品有限公司 Eurotium cristatum fermented soybean meal with constipation relieving effect and preparation process thereof
CN115226899A (en) * 2022-07-25 2022-10-25 鲁东大学 Functional food for people suffering from hypertension and constipation and preparation method thereof

Similar Documents

Publication Publication Date Title
CN107242550A (en) A kind of male sterility tailored version clinical nutrition formula and preparation method thereof
CN106954847A (en) Ferment probiotic composition with function of relaxing bowel, using and process preparation
CN104739848A (en) Composition containing L-arabinose and tagatose as well as preparation method and drug application of composition
CN112956686A (en) Bowel relaxing composition and preparation method thereof
JP5596704B2 (en) Composition containing fucoxanthin extract
CN107183705A (en) A kind of relax bowel improves the functional food of constipation
CN106723087A (en) A kind of tablet containing kelp dietary fiber and preparation method thereof
CN105079309B (en) Composition for relaxing bowel
CN105211687A (en) A kind of composition and method of making the same and purposes
CN106690331A (en) Kelp dietary fiber granules and preparation method thereof
CN106102484A (en) For reducing the compositions comprising Flos abelmoschi manihot of absorption of dietary fat
CN110810855A (en) Dietary fiber composition with bowel relaxing function
CN108451979A (en) A kind of lycopene compound preparation and its application with auxiliary treatment prostate cancer
CN106729599A (en) A kind of pharmaceutical composition for increasing bone density and its production and use
CN107981351B (en) Dietary microcapsule particle for regulating body fat rate and preparation method thereof
ES2299576T3 (en) PREPARATION BASED ON CACTACEAE THAT HAS THE PROPERTY OF FIXING FATS AND PROCEDURE FOR OBTAINING THE SAME.
CN103610054B (en) Healthcare food with effects of reducing weight and facilitating feces excretion and preparation method thereof
CN104719914B (en) A kind of composition for improving gastrointestinal function and preparation method thereof
WO1997037674A1 (en) Substance originating in germinating seeds of gramineous plant and containing proteins and insoluble dietary fibers and use thereof
CN105433382B (en) A kind of maca composition and its preparation method and application
CN114259044A (en) Semen cassiae and fructus cannabis compound fermentation product, functional fruit and vegetable enzyme jelly and preparation method of fruit and vegetable enzyme jelly
RU2586770C2 (en) Method of preparing herbal extract
CN108653322A (en) A kind of composition with the functional health product for preventing metastases
JP3497362B2 (en) Anticancer drugs
KR100362025B1 (en) Tumor-angiogenesis inhibitor and pharmaceutical composition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20210615

RJ01 Rejection of invention patent application after publication